Menu

Johnson & Johnson Covid-19 Vaccine Rollout is Set for the U.S.

Plus500 | Tuesday 02 March 2021

Johnson & Johnson has begun distributing almost 4 million freshly FDA approved corona vaccines set for the U.S., and supply is expected to increase in the next few months.

vaccine

The Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) both approved the Johnson & Johnson COVID-19 vaccine over the weekend for emergency use in the U.S. as Corona cases remain untamed. This makes Johnson & Johnson the third company to receive authorisation for distribution in the U.S. 

The Johnson & Johnson vaccine is different to the already-distributed Pfizer (PFE) and Moderna (MRNA) vaccines, as it is the first of its kind to be given as a single dose, and does not require cold storage temperatures.

Despite the positive announcement, Johnson and Johnson (JNJ) shares dropped 0.5% after market close yesterday. 

AstraZeneca Sells Stake in Moderna for Over US$1 Billion

Moderna has had further developments since its first vaccine rollout began. AstraZenaca, the UK-based Anglo-Swedish drug manufacturer has sold its 7.7% stake in Moderna, with hopes of boosting company finances.

With a US$39 billion acquisition of Boston-based Alexion Pharmaceuticals, the Moderna sale positions AstraZeneca well, as this move hopes to expand AstraZeneca's presence in the pharmaceutical industry. Furthermore, both AstraZeneca and Moderna are committed to a continued partnership in other biotech projects, including disease treatment, cardiovascular, renal and metabolism, and oncological. 

Moderna (MRNA) shares rose 1.7% at market closure yesterday, and AstraZeneca (AZN.ST) jumped 1.2% during yesterday’s trading. The sale announcement may have been the reason for the uptrend.

With Johnson & Johnson’s fresh vaccine distribution and AstraZeneca’s sale, it remains to be seen how these biotech shares will react in the coming months.


Get more from Plus500

Expand Your Knowledge

Videos & Articles help you expand your trading knowledge.

Prepare Your Trades

Our Economic calendar helps you explore global market events.

Trade Without Surprises

Understand the full costs of your trades now for better expense management later.


This information is written by Plus500 Ltd. The information is provided for general purposes only, and does not take into account any personal circumstances or objectives. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. No representation or warranty is given as to the accuracy or completeness of this information. It does not constitute financial, investment or other advice on which you can rely. Any references to past performance, historical returns, future projections, and statistical forecasts are no guarantee of future returns or future performance. Plus500 will not be held responsible for any use that may be made of this information and for any consequences that may result from such use. Hence, any person acting based on this information does so at their own discretion. The information has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

Need Help?
24/7 Support